Navigation Links
Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
Date:10/15/2009

HOLLYWOOD, Fla. and PRINCETON, N.J., Oct. 15 /PRNewswire/ -- Azopharma Product Development Group, LLC, a leader in preclinical and pharmaceutical product development services and PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, are pleased to announce the completion of a business development and co-promotion alliance to leverage complementary services, develop business opportunities, and jointly manage projects for certain services provided by the two companies.

Phil Meeks, chief executive officer, Azopharma Product Development Group commented "This agreement is an exciting opportunity for both of our organizations. Both companies will be introduced to new sets of clients and the clients will be exposed to new compelling solutions for their early phase development."

Jeffrey P. McMullen, president and chief executive officer, PharmaNet Development Group agrees, "PharmaNet's and Azopharma's services complement each other. Azopharma is an established provider of in vivo services with pre-clinical and toxicology capabilities and our bioanalytical capabilities are ideally positioned to support these studies."

About Azopharma Product Development Group, LLC

Azopharma Product Development Group, The Total Product Development Company(TM) is FDA registered, DEA approved and client audited on a regular basis. In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our South Florida facilities as well as our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact us at development@azopdogroup.com.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit their website at www.pharmanet.com.

    Azopharma Product Development Group, LLC
    Contact: Phil Meeks
    Phone: 954-433-7480
    development@azopharma.com

    PharmaNet Development Group, Inc.
    Contact: Anne-Marie Hess
    Phone: 609-951-6842
    ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.; Azopharma Product Development Group, LLC


'/>"/>
SOURCE PharmaNet Development Group, Inc.; Azopharma Product Development Group, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
3. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
4. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
5. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
6. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
7. VELOCITY Broadcasting Appoints Senior Director of Strategic Business Development
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
10. Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinsons Therapeutic Development in 2010
11. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):